Article
Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.
Cancer - 1 Sept 2002
Kirkwood John M, Richards Thomas, Zarour Hassane M, Sosman Jeffrey, Ernstoff Marc, Whiteside Theresa L, Ibrahim Joseph, Blum Ronald, Wieand Samuel, Mascari Ruth
Abstract excerpt
BACKGROUND: The clinical antitumor activity of recombinant interferon alpha2b (IFNalpha2b) has been well documented in patients with advanced and high-risk melanoma; however, its mechanism of action remains conjectural. Trial E2690 evaluated the immunomodulatory effects of IFNalpha2b in vivo during treatment at high doses (the HDI arm; n = 51 patients) and at low doses (the LDI arm; n = 54 patients) in relation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.